Paper Details

  1. Home
  2. Paper Details

Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).

Author: , AndriolaIleana, BarlatiStefano, BassettiRoberta, BellettiSandro, BellomoAntonello, BertolinoAlessandro, ChiaieRoberto Delle, ClericiMassimo, ConcaAndreas, De FazioPasquale, De FilippisSergio, Dell'OssoBernardo, Di LorenzoGiorgio, Di MauroStefania, Di NicolaMarco, FagioliniAndrea, MainaGiuseppe, MartiadisVassilis, MartinottiGiovanni, McIntyreRoger S, NicolòGiuseppe, NuciforaDomenica, OlivolaMiriam, PettorrusoMauro, RossoGianluca, SaniGabriele, SiracusanoAlberto, ValcheraAlessandro, VitaAntonio, d'AndreaGiacomo, di GiannantonioMassimo

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This real-world study of 116 patients with treatment-resistant depression (TRD) treated with esketamine nasal spray found a significant reduction in depressive symptoms and a dramatic increase in clinical response and remission rates. No unexpected safety concerns were observed.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment-resistant Depression (TRD) represents a widespread disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer of ketamine, has been recently approved for TRD, but real-world studies are needed to prove its efficacy in naturalistic settings. OB...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jad.2022.09.043

データ提供：米国国立医学図書館（NLM）

Esketamine: A Refreshing Oasis in the Desert of Treatment-Resistant Depression

This study investigates the use of esketamine, a nasal spray form of the anesthetic ketamine, for treating treatment-resistant depression (TRD), a condition that doesn't respond to conventional antidepressant medications. The authors examined the effectiveness and safety of esketamine in real-world clinical settings.

Esketamine: A Promising Treatment Approach

The study found that esketamine significantly reduced depressive symptoms in patients with TRD, with a substantial increase in clinical response and remission rates. This is like finding a refreshing oasis in the vast and unforgiving desert of TRD.

Treatment-Resistant Depression: A Desert of Despair

TRD is a debilitating condition that can significantly impact a person's quality of life. This research offers a glimmer of hope for patients struggling with this difficult condition.

Dr.Camel's Conclusion

Esketamine's effectiveness in real-world settings for TRD is a significant finding. It's like a beacon of light in the desert of mental health challenges, offering a potential solution to a difficult and widespread problem.
Date :
  1. Date Completed 2022-11-15
  2. Date Revised 2022-12-09
Further Info :

Pubmed ID

36167246

DOI: Digital Object Identifier

10.1016/j.jad.2022.09.043

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.